(CercleFinance.com) – GeNeuro rose on the stock market this Wednesday following the publication of two studies demonstrating the neurotoxic role of endogenous human retrovirus K in patients with Charcot’s disease and the relevance of a targeted therapy.
The Swiss biopharmaceutical company reported this morning on the publication in the scientific journal Annals of Neurology of the results from its collaboration with the National Institute of Neurological Disorders and Stroke (NINDS).
According to GeNeuro, these findings confirm the relevance of its approach in sporadic amyotrophic lateral sclerosis (ALS) via its new monoclonal antibody GN-K01.
This antibody inhibits the neurotoxic effects of the HERV-K ENV protein, an endogenous toxin detected in patients’ cerebrospinal fluid that leads to neuronal cell death.
Following this information, the GeNeuro share rose by 4.2% on Wednesday morning on the Paris Stock Exchange.